SB 204990 manufacturers
- SB 204990
-
- $39.00 / 1mg
-
2025-04-28
- CAS:154566-12-8
- Min. Order:
- Purity: 99.6%
- Supply Ability: 10g
|
| | SB 204990 Basic information |
| Product Name: | SB 204990 | | Synonyms: | SB 204990;3-Furanacetic acid, 5-[6-(2,4-dichlorophenyl)hexyl]tetrahydro-3-hydroxy-2-oxo-, (3R,5S)-rel-;2-((3R,5S)-5-(6-(2,4-dichlorophenyl)hexyl)-3-hydroxy-2-oxotetrahydrofuran-3-yl)acetic acid;(3R,5S)-rel-5-[6-(2,4-Dichlorophenyl)hexyl]tetrahydro-3-hydroxy-2-oxo-3-furanacetic acid;YTRNLFYTHYWDAU-KDOFPFPSSA-N;SB-204990(racemic);SB204990,Inhibitor,inhibit,ACLY,SB 204990,ATP Citrate Lyase,SB-204990;2-((3S,5R)-5-(6-(2,4-Dichlorophenyl)hexyl)-3-hydroxy-2-oxotetrahydrofuran-3-yl)acetic acid | | CAS: | 154566-12-8 | | MF: | C18H22Cl2O5 | | MW: | 389.27 | | EINECS: | | | Product Categories: | | | Mol File: | 154566-12-8.mol |  |
| | SB 204990 Chemical Properties |
| Melting point | 87-89 °C | | Boiling point | 571.6±40.0 °C(Predicted) | | density | 1.332±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMF: 30 mg/ml; DMF:PBS(pH7.2) (1:2): 0.33 mg/ml; DMSO: 20 mg/ml; Ethanol: 1 mg/ml | | form | A crystalline solid | | pka | 4.33±0.10(Predicted) | | color | White to off-white | | InChI | InChI=1/C18H22Cl2O5/c19-13-8-7-12(15(20)9-13)5-3-1-2-4-6-14-10-18(24,11-16(21)22)17(23)25-14/h7-9,14,24H,1-6,10-11H2,(H,21,22)/t14-,18+/s3 | | InChIKey | YTRNLFYTHYWDAU-RVFWCEGZNA-N | | SMILES | O1[C@@H](CCCCCCC2=CC=C(Cl)C=C2Cl)C[C@@](O)(CC(O)=O)C1=O |&1:1,17,r| |
| | SB 204990 Usage And Synthesis |
| Uses | SB 204990 is a prodrug of the potent ATP citrate-lyase inhibitor SB-201076. | | Biological Activity | SB-204990 is a cell-permeable and orally available γ-lactone prodrug of the non-cell-permeable SB-201076 th at inhibits human and r at ATP citrate-lyase (Ki =1 μM against human and r at ACL) in a predominantly competitive manner with a small but significant uncompetitive component. SB-204990 treatment is shown to suppress the rate of cellular cholesterol and fatty acid synthesis in HepG2 cultures (by 91% & 82%, respectively, with 30 μM SB-204990), and display hypocholesterolaemic and hypolipidaemic efficacy in vivo when administered in the diet (0.05-0.25%, w/w; mice, rats, dogs). | | in vivo | SB 204990, when administered orally to rats, is absorbed into the systemic circulation. When administered in the diet (0.05-0.25%, w/w) for 1 week, SB 204990 causes a dose-related decrease in plasma cholesterol (by up to 46%) and triglyceride levels (by up to 80%) in rats. SB 204990 (25 mg/kg per day) also decreases plasma cholesterol levels (by up to 23%) and triglyceride levels (by up to 38%) in the dog, preferentially decreasing low-density lipoprotein compared with high-density lipoprotein cholesterol levels[2]. | | storage | Store at -20°C |
| | SB 204990 Preparation Products And Raw materials |
|